International Journal of Hematology

, 82:100

FLT3 Tyrosine Kinase Inhibitors

Article

DOI: 10.1532/IJH97.05079

Cite this article as:
Levis, M. & Small, D. Int J Hematol (2005) 82: 100. doi:10.1532/IJH97.05079

Abstract

The receptor tyrosine kinase FLT3 is an important regulatory molecule in hematopoiesis and is expressed on the blasts in most cases of acute leukemia. Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are associated with a distinctly worse clinical outcome. Efforts to target this mutation and improve outcomes in this subgroup of AML patients have led to the investigation of several novel small-molecule FLT3 tyrosine kinase inhibitors. These compounds derive from a wide variety of chemical classes and differ significantly, both in their potency and in their selectivity. In this review, we discuss the results of preclinical, clinical, and correlative laboratory studies of FLT3 inhibitors in demonstrating how this field represents a truly translational enterprise with multiple ongoing interactions between the laboratory and the clinic.

Key words

FLT3InhibitorsReceptor tyrosine kinaseAMLHematopoiesis

Copyright information

© The Japanese Society of Hematology 2005

Authors and Affiliations

  1. 1.Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA